Peptide Library / Detail
Ovagen
Half-life
30-60 minutes
Delivery
Subcutaneous or intramuscular injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Ovagen is a short bioregulator peptide consisting of the amino acid sequence Glu-Asp-Gly (EDG). It is classified as a cytomax or cytogen peptide, theorized to interact with DNA to support cellular function in ovarian tissue. Ovagen belongs to the family of organ-specific peptide bioregulators developed through research on tissue-specific peptide complexes.
Usage
Research protocols typically employ 10-20 mg administered subcutaneously or intramuscularly over a 10-20 day cycle. Common regimens involve once-daily injections for 10 consecutive days, with cycles repeated every 3-6 months depending on research objectives. Some protocols combine Ovagen with other bioregulators for synergistic tissue support studies.
Mechanism of Action
Ovagen is proposed to act as a short peptide bioregulator that influences gene expression in ovarian cells through interaction with chromatin and DNA regulatory regions. The tripeptide sequence Glu-Asp-Gly may facilitate tissue-specific signaling pathways related to follicular development, oocyte maturation, and ovarian cellular homeostasis. The mechanism parallels research on FSH-mediated follicular dynamics and oocyte developmental competence observed in various mammalian models.
Benefits(6)
- May support ovarian tissue function and cellular health
- Potentially assists in follicular development processes
- Could promote oocyte quality and maturation
- May help maintain reproductive tissue homeostasis
- Potentially supports hormonal balance related to ovarian function
- Could assist in age-related ovarian tissue maintenance
Side Effects(6)
- Injection site reactions including redness or mild discomfort
- Potential allergic reactions in sensitive individuals
- Temporary hormonal fluctuations
- Mild headache or fatigue during initial administration
- Possible gastrointestinal discomfort
- Unknown long-term effects due to limited human clinical data